Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (23792360) | ||||||||||||
| Authors | Yao HP, Zhou YQ, Zhang R, Wang MH | ||||||||||||
| Title | MSP-RON signalling in cancer: pathogenesis and therapeutic potential. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | Since the discovery of MSP (macrophage-stimulating protein; also known as MST1 and hepatocyte growth factor-like (HGFL)) as the ligand for the receptor tyrosine kinase RON (also known as MST1R) in the early 1990s, the roles of this signalling axis in cancer pathogenesis has been extensively studied in various model systems. Both in vitro and in vivo evidence has revealed that MSP-RON signalling is important for the invasive growth of different types of cancers. Currently, small-molecule inhibitors and antibodies blocking RON signalling are under investigation. Substantial responses have been achieved in human tumour xenograft models, laying the foundation for clinical validation. In this Review, we discuss recent advances that demonstrate the importance of MSP-RON signalling in cancer and its potential as a therapeutic target. | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK8033 | MK-8033|HQP8361|HQP 8361|HQP-8361|MK 8033 | MET Inhibitor 59 RON Inhibitor 11 | MK8033 is an inhibitor of MET and MST1R (RON) that suppresses mTOR signaling, potentially resulting in reduced survival and colony formation, increased apoptosis, and inhibition of tumor growth (PMID: 23792360, PMID: 33163272). |
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|